Flonase Generic Launch Blocked; Glaxo Drops Switch Plan
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline has shelved an OTC switch of Flonase nasal steroid as a competitive strategy in favor of litigation to block generics